YY1下调是对分子向药物的治疗反应的基础
Shichao Zhou1,2, Jingyu Zang3, Mei-Chun Cai1
1State Key Laboratory of Systems Medicine for Cancer, Department of Thoracic Surgery, Shanghai Cancer Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Cell death & disease
|November 28, 2024
概括
转录因子阴阳1 (YY1) 通过调节细胞循环和自来驱动癌症药物耐药性. 抑制YY1增强了向治疗的有效性,并防止了肺癌的耐药性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 针对性癌症疗法面临药物耐药性的挑战.
- 癌细胞从药物敏感到耐药状态的进化路径尚未完全理解.
- 了解耐药性的分子机制对于改善治疗结果至关重要.
研究的目的:
- 阐明治疗诱导的癌症进化和耐药性的分子基础.
- 调查转录因子阴阳1 (YY1) 对向激酶抑制剂的反应中的作用.
- 确定YY1作为克服耐药性的潜在治疗标.
主要方法:
- 采用了一种多方面的方法,包括药理上抑制受体氨酸激酶 (RTK) /甲基因激活蛋白激酶 (MAPK) 途径.
- 评估了YY1.1的转录调节和功能作用.
- 在肺腺癌的临床样本上进行了免疫组织化学分析.
主要成果:
- 对RTK/MAPK通路的药理抑制降低了YY1转录的调节,YY1转录在治疗逃逸后恢复.
- 如果不能降低YY1水平,会损害细胞毒性作用并促进抗性.
- 消除剩余的YY1最大限度地提高了抗癌效果,并防止了耐药性.
- 发现YY1调节细胞周期和自程序.
- YY1在肺腺癌中无处不在表达,并且在RTK/MAPK抑制下显示出动态变化.
结论:
- 转录因子YY1在各种向激酶抑制剂的药物耐药性出现中起着趋同作用.
- 在基因型导向癌症治疗的背景下,YY1 作为一个关键的决定性节点.
- 向YY1可能是一个可行的策略,以提高向癌症治疗的疗效和克服耐药性.
相关概念视频
Receptor Downregulation in MVBs
2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.0K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Desensitization and Tachyphylaxis
1.5K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
147
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
147
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


